カンナビジオール (Japanese Wikipedia)

DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").

doi.org

“Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol 42 (11 Suppl): 11S–19S. (November 2002). doi:10.1177/0091270002238789. PMID 12412831.
“Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res 23 (5): 597–602. (May 2009). doi:10.1002/ptr.2625. PMID 18844286.
^{[信頼性の低い医学の情報源？]} “Cannabis and cannabis extracts: greater than the sum of their parts?”. Journal of Cannabis Therapeutics 1 (3/4): 103–132. (2001). doi:10.1300/J175v01n03_08.
“The pharmacologic and clinical effects of medical cannabis”. Pharmacotherapy 33 (2): 195–209. (February 2013). doi:10.1002/phar.1187. PMID 23386598.
Aizpurua-Olaizola, Oier (February 2, 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes” (英語). Journal of Natural Products 79 (2): 324–331. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
渡辺正仁、早崎華、由留木裕子、渡辺克哉「カンナビジオールの治療効果とその作用機序」『保健医療学雑誌』第9巻第2号、2018年、112–125頁。doi:10.15563/jalliedhealthsci.9.112。NAID 130007492289。
“Cannabinoids for epilepsy”. Cochrane Database Syst Rev 6 (6): CD009270. (June 13, 2012). doi:10.1002/14651858.CD009270.pub2. PMID 22696383.
Amy Maxmen. “大麻由来の抗てんかん薬が米国で承認”. Nature ダイジェスト. doi:10.1038/ndigest.2018.181015. 2021年1月17日閲覧。
Maa, Edward (2014). “The case for medical marijuana in epilepsy”. Epilepsia 55 (6): 783–786. doi:10.1111/epi.12610. ISSN 0013-9580.
“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.
Schubart CD et al (2013). “Cannabidiol as a potential treatment for psychosis”. European Neuropsychopharmacology 24 (1): 51–64. doi:10.1016/j.euroneuro.2013.11.002. PMID 24309088.
McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; et al. (2017年). "Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial". American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17030325. PMID 29241357。
Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients". Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846。
Palmieri B, Laurino C, Vadalà M (2019). “A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars”. Clin Ter 170 (2): e93–e99. doi:10.7417/CT.2019.2116. PMID 30993303.
Devinsky O (Jun 2014). “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
“Cannabidiol—recent advances”. Chem. Biodivers. 4 (8): 1678–92. (August 2007). doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin”. British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
“Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism”. Brain Research 1188: 157–164. (2008). doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
“The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (7): 1092–101. (2007). doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Russo, Ethan B.; Burnett, Andrea; Hall, Brian; et al. (2005年). "Agonistic Properties of Cannabidiol at 5-HT1a Receptors". Neurochemical Research. 30 (8): 1037–1043. doi:10.1007/s11064-005-6978-1. PMID 16258853。
“Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology 159 (1): 122–8. (January 2010). doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
“5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats”. British Journal of Pharmacology 156 (1): 181–8. (January 2009). doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
“Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology 199 (2): 223–30. (August 2008). doi:10.1007/s00213-008-1168-x. PMID 18446323.
“Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke; a Journal of Cerebral Circulation 36 (5): 1077–82. (May 2005). doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890.
“Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology 52 (4): 1079–87. (March 2007). doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
“Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 372 (5): 354–361. (2006). doi:10.1007/s00210-006-0033-x. PMID 16489449.
“Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3364–78. (December 2012). doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
“Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy”. Cannabis and Cannabinoid Research 1 (1): 90–101. (2014). doi:10.1089/can.2015.0012.
“Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats”. Psychopharmacology 218 (2): 443–457. (November 2011). doi:10.1007/s00213-011-2342-0. PMID 21667074.
“Evidence that Cannabidiol Does Not Significantly Alter the Pharmacokinetics of Tetrahydrocannabinol in Man”. Journal of Pharmacokinetics and Biopharmaceutics 9 (3): 245–260. (June 1981). doi:10.1007/BF01059266. PMID 6270295.
Gaston, Tyler E.; Bebin, E. Martina; Cutter, Gary R.; et al. (2017年). "Interactions between cannabidiol and commonly used antiepileptic drugs". Epilepsia. 58 (9): 1586–1592. doi:10.1111/epi.13852. PMID 28782097。
“Cannabidiol”. Acta Crystallogr. B 33 (10): 3211–3214. (1977). doi:10.1107/S0567740877010577.
“Hashish—XIII On the nature of the beam test”. Tetrahedron 24 (16): 5615–5624. (1968). doi:10.1016/0040-4020(68)88159-1. PMID 5732891.
“Synthese und Chiralität des (−)-Cannabidiols”. Helv. Chim. Acta 50 (2): 719–723. (1967). doi:10.1002/hlca.19670500235. PMID 5587099.
“Boron trifluoride etherate on alumuna — a modified Lewis acid reagent. An improved synthesis of cannabidiol”. Tetrahedron Letters 26 (8): 1083–1086. (1985). doi:10.1016/S0040-4039(00)98518-6.
“Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate”. Org. Lett. 8 (13): 2699–2702. (2006). doi:10.1021/ol060692h. PMID 16774235.
“Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa”. Journal of Experimental Botany 60 (13): 3715–3726. (2009). doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y., Morimoto, S. (2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. FEBS Letters 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.
Sachs J et al (Oct 2015). “Safety and Toxicology of Cannabinoids”. Neurotherapeutics 12 (4): 735–746. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
“A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophr. Res. 162 (1–3): 153–61. (2015). doi:10.1016/j.schres.2015.01.033. PMID 25667194.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). "Broad-Scale Genetic Diversity of Cannabis for Forensic Applications". PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530。
Fournier, G. (2003). “Intérêt du rapport Δ-9-THC / CBD dans le contrôle des cultures de chanvre industriel”. Annales de Toxicologie Analytique 15 (4): 250–259. doi:10.1051/ata/2003003.

doseofnature.com

“Marijuana stops child's severe seizures”. CNN. January 7, 2016閲覧。

dravetfoundation.org

“What is Dravet Syndrome?”. Dravetfoundation.org (June 20, 2014). December 4, 2016閲覧。

eiha.org

“Support the EIHA CBD position paper - EIHA European Industrial Hemp Association”. 2018年9月23日閲覧。

epilepsyresearch.org.uk

“Cannabis-Derived Dravet Syndrome Drug Gets US Orphan Drug Approval” (November 18, 2013). July 21, 2015閲覧。

europa.eu

ec.europa.eu

“CosIng – Cosmetics – GROWTH – European Commission”. Ec.europa.eu. December 4, 2016閲覧。

fda.gov

“Cannabidiol: Barriers to Research and Potential Medical Benefits”. FDA (June 24, 2015). December 15, 2015閲覧。

fsai.ie

“CBD Oils and Hemp Oils - Legal Status”. 2018年9月23日閲覧。

globenewswire.com

"GW Pharmaceuticals Receives Orphan Drug Designation from the European Medicines Agency (EMA) for Cannabidiol for the Treatment of Tuberous Sclerosis" (Press release). Nasdaq. 27 February 2018. 2018年3月25日閲覧。

gov.uk

“MHRA statement on products containing Cannabidiol (CBD)”. Gov.uk. (December 14, 2016)

greenzonejapan.wordpress.com

“Project CBD 主催者マーチン・リーに訊く”. GREEN ZONE JAPAN (2018年2月14日). 2018年3月1日閲覧。

hc-sc.gc.ca

“Fact Sheet — Sativex”. Health Canada. May 16, 2013閲覧。

justice.gc.ca

laws-lois.justice.gc.ca

“Controlled Drugs and Substances Act – Schedule II”. Laws-lois.justice.gc.ca. December 4, 2016閲覧。

kenkyuukai.jp

cannabis.kenkyuukai.jp

World Health Organization、日本臨床カンナビノイド学会『カンナビジオール（CBD）事前審査報告書 (pdf)』（レポート）、世界保健機関、2017年12月6日。2017年12月5日閲覧。 [1] World Health Organization (2017年12月6日). CANNABIDIOL Pre-Review Report Agenda Item 5.2 : Expert Committee on Drug Dependence Thirty-ninth Meeting (pdf) (Report). 世界保健機関. 2017年12月5日閲覧。
テドロス・アダノム・ゲブレシウス、(訳)日本臨床カンナビノイド学会 (23 July 2018). 国連事務総長（アントニオ・グテーレス氏）への手紙 (pdf) (Report). 世界保健機関. 2019年1月15日閲覧。原文：ECDD 40th meetingのDirector-General letter 。翻訳文書の経緯：“2018年6月第40回WHO ECDD会議の結果について”. 日本臨床カンナビノイド学会 (2018年9月3日). 2019年1月15日閲覧。
“欧州連合司法裁判所の20年11月19日判決「CBDは麻薬ではない」”. 日本臨床カンナビノイド学会 (2021年1月26日). 2021年1月28日閲覧。

kentucky.com

“Hemp industry is growing in Kentucky, attracting processors, investment | Lexington Herald-Leader”. Kentucky.com (May 5, 2015). December 4, 2016閲覧。

latimes.com

articles.latimes.com

“On the frontier of medical pot to treat boy's epilepsy”. (September 13, 2012)

legislation.gov.au

“Poisons Standard March 2016”. Legislation.gov.au. December 4, 2016閲覧。

m3.com

“カンナビジオール医薬品の早期承認を要望日本てんかん学会”. m3.com (2019年9月23日). 2021年1月17日閲覧。

medicaldaily.com

“Marijuana's Main Ingredient, Cannabidiol, May Be An Effective Way To Treat Epilepsy”. Medical Daily. (December 8, 2015) December 14, 2015閲覧。

medicines.org.uk

“Sativex Oromucosal Spray – Summary of Product Characteristics (SPC) – (eMC)”. Medicines.org.uk. December 4, 2016閲覧。

medscape.com

Melville, Nancy A. (August 14, 2013), Seizure Disorders Enter Medical Marijuana Debate, Medscape Medical News. January 14, 2014閲覧。

mhlw.go.jp

ncd.mhlw.go.jp

関東信越厚生局麻薬取締部 (2020年5月). “CBD製品の大麻非該当性の確認について”. 麻薬取締部ウェブサイト. 2021年1月17日閲覧。手続きに関する付属のPDFも参照。

nature.com

Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients". Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846。

natureasia.com

Amy Maxmen. “大麻由来の抗てんかん薬が米国で承認”. Nature ダイジェスト. doi:10.1038/ndigest.2018.181015. 2021年1月17日閲覧。

ncsl.org

State Industrial Hemp Statutes.

newsweek.com

“The Great Kentucky Hemp Experiment”. Newsweek.com (October 23, 2015). December 4, 2016閲覧。

nih.gov

pubmed.ncbi.nlm.nih.gov

“Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol 42 (11 Suppl): 11S–19S. (November 2002). doi:10.1177/0091270002238789. PMID 12412831.
“Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res 23 (5): 597–602. (May 2009). doi:10.1002/ptr.2625. PMID 18844286.
“The pharmacologic and clinical effects of medical cannabis”. Pharmacotherapy 33 (2): 195–209. (February 2013). doi:10.1002/phar.1187. PMID 23386598.
Aizpurua-Olaizola, Oier (February 2, 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth ofCannabis sativaPlants from Different Chemotypes” (英語). Journal of Natural Products 79 (2): 324–331. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
“Cannabinoids for epilepsy”. Cochrane Database Syst Rev 6 (6): CD009270. (June 13, 2012). doi:10.1002/14651858.CD009270.pub2. PMID 22696383.
“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.
Schubart CD et al (2013). “Cannabidiol as a potential treatment for psychosis”. European Neuropsychopharmacology 24 (1): 51–64. doi:10.1016/j.euroneuro.2013.11.002. PMID 24309088.
McGuire, Philip; Robson, Philip; Cubala, Wieslaw Jerzy; et al. (2017年). "Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial". American Journal of Psychiatry: appi.ajp.2017.1. doi:10.1176/appi.ajp.2017.17030325. PMID 29241357。
Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients". Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846。
Palmieri B, Laurino C, Vadalà M (2019). “A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars”. Clin Ter 170 (2): e93–e99. doi:10.7417/CT.2019.2116. PMID 30993303.
Devinsky O (Jun 2014). “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
“Cannabidiol—recent advances”. Chem. Biodivers. 4 (8): 1678–92. (August 2007). doi:10.1002/cbdv.200790147. PMID 17712814.
Pertwee RG (2008). “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin”. British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
“Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism”. Brain Research 1188: 157–164. (2008). doi:10.1016/j.brainres.2007.09.090. PMID 18021759.
“The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (7): 1092–101. (2007). doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
Russo, Ethan B.; Burnett, Andrea; Hall, Brian; et al. (2005年). "Agonistic Properties of Cannabidiol at 5-HT1a Receptors". Neurochemical Research. 30 (8): 1037–1043. doi:10.1007/s11064-005-6978-1. PMID 16258853。
“Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology 159 (1): 122–8. (January 2010). doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
“5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats”. British Journal of Pharmacology 156 (1): 181–8. (January 2009). doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
“Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats”. Psychopharmacology 199 (2): 223–30. (August 2008). doi:10.1007/s00213-008-1168-x. PMID 18446323.
“Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism”. Stroke; a Journal of Cerebral Circulation 36 (5): 1077–82. (May 2005). doi:10.1161/01.STR.0000163083.59201.34. PMID 15845890.
“Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance”. Neuropharmacology 52 (4): 1079–87. (March 2007). doi:10.1016/j.neuropharm.2006.11.005. PMID 17320118.
“Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors”. Naunyn-Schmiedeberg's Archives of Pharmacology 372 (5): 354–361. (2006). doi:10.1007/s00210-006-0033-x. PMID 16489449.
“Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3364–78. (December 2012). doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
“Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain”. Drug Metabolism and Disposition 23 (8): 825–831. (August 1995). PMID 7493549.
“Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats”. Psychopharmacology 218 (2): 443–457. (November 2011). doi:10.1007/s00213-011-2342-0. PMID 21667074.
“Evidence that Cannabidiol Does Not Significantly Alter the Pharmacokinetics of Tetrahydrocannabinol in Man”. Journal of Pharmacokinetics and Biopharmaceutics 9 (3): 245–260. (June 1981). doi:10.1007/BF01059266. PMID 6270295.
Gaston, Tyler E.; Bebin, E. Martina; Cutter, Gary R.; et al. (2017年). "Interactions between cannabidiol and commonly used antiepileptic drugs". Epilepsia. 58 (9): 1586–1592. doi:10.1111/epi.13852. PMID 28782097。
“Hashish—XIII On the nature of the beam test”. Tetrahedron 24 (16): 5615–5624. (1968). doi:10.1016/0040-4020(68)88159-1. PMID 5732891.
“Synthese und Chiralität des (−)-Cannabidiols”. Helv. Chim. Acta 50 (2): 719–723. (1967). doi:10.1002/hlca.19670500235. PMID 5587099.
“Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate”. Org. Lett. 8 (13): 2699–2702. (2006). doi:10.1021/ol060692h. PMID 16774235.
“Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa”. Journal of Experimental Botany 60 (13): 3715–3726. (2009). doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
Taura, F., Sirikantaramas, S., Shoyama, Y., Yoshikai, K., Shoyama, Y., Morimoto, S. (2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. FEBS Letters 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.
Sachs J et al (Oct 2015). “Safety and Toxicology of Cannabinoids”. Neurotherapeutics 12 (4): 735–746. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
“A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophr. Res. 162 (1–3): 153–61. (2015). doi:10.1016/j.schres.2015.01.033. PMID 25667194.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
“Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb”. Trends Pharmacol. Sci. 30 (10): 515–27. (2009). doi:10.1016/j.tips.2009.07.006. PMID 19729208.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). "Broad-Scale Genetic Diversity of Cannabis for Forensic Applications". PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530。

ncbi.nlm.nih.gov

Bergamaschi, Mateus M; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; et al. (2011年). "Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients". Neuropsychopharmacology. 36 (6): 1219–1226. doi:10.1038/npp.2011.6. PMC 3079847. PMID 21307846。
Devinsky O (Jun 2014). “Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. Epilepsia 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
Pertwee RG (2008). “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin”. British Journal of Pharmacology 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC 2219532. PMID 17828291.
“The orphan receptor GPR55 is a novel cannabinoid receptor”. British Journal of Pharmacology 152 (7): 1092–101. (2007). doi:10.1038/sj.bjp.0707460. PMC 2095107. PMID 17876302.
“Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors”. British Journal of Pharmacology 159 (1): 122–8. (January 2010). doi:10.1111/j.1476-5381.2009.00521.x. PMC 2823358. PMID 20002102.
“5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats”. British Journal of Pharmacology 156 (1): 181–8. (January 2009). doi:10.1111/j.1476-5381.2008.00046.x. PMC 2697769. PMID 19133999.
“Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 367 (1607): 3364–78. (December 2012). doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
“Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa”. Journal of Experimental Botany 60 (13): 3715–3726. (2009). doi:10.1093/jxb/erp210. PMC 2736886. PMID 19581347.
Sachs J et al (Oct 2015). “Safety and Toxicology of Cannabinoids”. Neurotherapeutics 12 (4): 735–746. doi:10.1007/s13311-015-0380-8. PMC 4604177. PMID 26269228.
Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). "Broad-Scale Genetic Diversity of Cannabis for Forensic Applications". PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530。

pmc.ncbi.nlm.nih.gov

nii.ac.jp

ci.nii.ac.jp

渡辺正仁、早崎華、由留木裕子、渡辺克哉「カンナビジオールの治療効果とその作用機序」『保健医療学雑誌』第9巻第2号、2018年、112–125頁。doi:10.15563/jalliedhealthsci.9.112。NAID 130007492289。

nytimes.com

Shear, Michael D. (February 7, 2014) In Signing Farm Bill, Obama Extols Rural Growth.

pharmtech.com

“EMA Grants Orphan Drug Designation to Epidiolex for Treatment of Lennox-Gastaut Syndrome”. Pharmatech 2017年9月15日閲覧。

plos.org

journals.plos.org

Scali, Monica; Dufresnes, Christophe; Jan, Catherine; et al. (2017年). "Broad-Scale Genetic Diversity of Cannabis for Forensic Applications". PLOS ONE. 12 (1): e0170522. doi:10.1371/journal.pone.0170522. PMC 5249207. PMID 28107530。

researchgate.net

“Therapeutic Potential of Cannabinoids in Psychosis”. Biol. Psychiatry 79 (7): 604–12. (2016). doi:10.1016/j.biopsych.2015.11.018. PMID 26852073.

telegraph.co.uk

“Growing marijuana that won't get you high”. London. (October 26, 2010)

tjapan.jp

Naho Sasaki (2019年4月2日). “コスメティックは未来を変えられるか？Vol.2 現代人の救世主「CBDオイル」”. T JAPAN:The New York Times Style Magazine. 2021年1月28日閲覧。

uocc.co.jp

oem.uocc.co.jp

CBDのOEMメーカー

uspto.gov

patft.uspto.gov

wa.gov

lawfilesext.leg.wa.gov

HOUSE BILL REPORT SSB 5012. leg.wa.gov

who.int

“International Nonproprietary Names for Pharmaceutical Substances (INN)”. WHO Drug Information 30 (2): 241. (2016).
World Health Organization、日本臨床カンナビノイド学会『カンナビジオール（CBD）事前審査報告書 (pdf)』（レポート）、世界保健機関、2017年12月6日。2017年12月5日閲覧。 [1] World Health Organization (2017年12月6日). CANNABIDIOL Pre-Review Report Agenda Item 5.2 : Expert Committee on Drug Dependence Thirty-ninth Meeting (pdf) (Report). 世界保健機関. 2017年12月5日閲覧。
テドロス・アダノム・ゲブレシウス、(訳)日本臨床カンナビノイド学会 (23 July 2018). 国連事務総長（アントニオ・グテーレス氏）への手紙 (pdf) (Report). 世界保健機関. 2019年1月15日閲覧。原文：ECDD 40th meetingのDirector-General letter 。翻訳文書の経緯：“2018年6月第40回WHO ECDD会議の結果について”. 日本臨床カンナビノイド学会 (2018年9月3日). 2019年1月15日閲覧。

worldcat.org

search.worldcat.org

Maa, Edward (2014). “The case for medical marijuana in epilepsy”. Epilepsia 55 (6): 783–786. doi:10.1111/epi.12610. ISSN 0013-9580.